• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

mrd@unimelb.edu.au

Credentials


Position
Honorary Conjoint Senior Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-8056-5348

DR Mark Dowling

Honorary Conjoint Senior Fellow
The Sir Peter MacCallum Department of Oncology

94 Scholarly works
4 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Richter transformation: emerging immunologic strategies beyond chemoimmunotherapy.
    DOI: 10.1182/bloodadvances.2026020197
  • 2026

    Journal article

    Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.
    DOI: 10.1182/bloodadvances.2026021618
  • 2026

    Journal article

    Pre-transplant azacitidine does not improve survival in allogeneic HSCT for higher-risk MDS
    DOI: 10.1038/s41409-026-02874-5
  • 2026

    Journal article

    Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study.
    DOI: 10.1016/j.cmi.2026.06.019
  • 2026

    Research grants (ARC, NHMRC, MRFF)

    Next Generation Cellular Immunotherapy for Multiple Myeloma and Beyond
  • 2025

    Research grants (other domestic)

    Clinical, Laboratory and Radiological Predictive Factors for Safety and Efficacy of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Australia: A Multi-Centre Real-World Study
  • 2022

    Research grants (other domestic)

    Adjuvant Immunotherapy to Improve the Efficacy, Durability, and Cost Effectiveness of CAR T-Cell Therapy for Aggressive Lymphoma
Mark Dowling

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Infections in the First 30 Days after Chimeric Antigen Receptor T-Cell Therapy in Patients Not Receiving Fluoroquinolone Prophylaxis.
    DOI: 10.1016/j.jtct.2026.03.040
  • 2026

    Journal article

    Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
    DOI: 10.1182/blood.2025032307
  • 2026

    Journal article

    DEVELOPMENT AND CLINICAL DELIVERY OF AN AUSTRALIAN-MANUFACTURED CD19 CAR-T CELL THERAPY: THE PLATYPS STUDY
    DOI: 10.1016/j.jcyt.2026.102647
  • 2026

    Journal article

    Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas
    DOI: 10.1080/10428194.2025.2579721
  • 2026

    Journal article

    Neurological implications of chimeric antigen receptor-T cell therapy
    DOI: 10.1136/bmjno-2025-001491
  • 2026

    Journal article

    A Critical Review of Clinical Factors and Tools for Predicting Chimeric Antigen Receptor T-Cell Toxicities
    DOI: 10.1016/j.jtct.2026.05.027

RECENT PROJECTS

  • 2026

    Research grants (other domestic)

    Development of a Novel Nanobody-Secreting CAR-T Cell for the Treatment of Multiple Myeloma

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224